James Hermiller
Overview
Explore the profile of James Hermiller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
2234
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lakkireddy D, Ellis C, Thaler D, Swarup V, Gambhir A, Hermiller J, et al.
J Am Coll Cardiol
. 2024 Nov;
PMID: 39570242
Background: The Amulet IDE trial (AMPLATZER Amulet Left Atrial Appendage Occluder [LAAO] Investigational Device Exemption [IDE] Trial) evaluated the safety and effectiveness of the Amulet occluder (Abbott) in patients with...
2.
Cothern B, Kourany M, Elsner G, Moainie S, Hermiller J
J Soc Cardiovasc Angiogr Interv
. 2024 Aug;
2(6Part A):101115.
PMID: 39129894
No abstract available.
3.
Cao D, Vranckx P, Valgimigli M, Sartori S, Angiolillo D, Bangalore S, et al.
EuroIntervention
. 2024 May;
20(10):e630-e642.
PMID: 38776146
Background: A short dual antiplatelet therapy (DAPT) duration has been proposed for patients at high bleeding risk (HBR) undergoing drug-eluting coronary stent (DES) implantation. Whether this strategy is safe and...
4.
Urey M, Hibbert B, Jorde U, Eckman P, Simard T, Labinaz M, et al.
Eur J Heart Fail
. 2024 Apr;
26(4):1065-1077.
PMID: 38606485
Aims: Patients with heart failure and mildly reduced or preserved ejection fraction have limited therapeutic options. The ALT-FLOW Early Feasibility Study evaluated safety, haemodynamics and outcomes for the APTURE transcatheter...
5.
Sardella G, Spirito A, Sartori S, Angiolillo D, Vranckx P, de la Torre Hernandez J, et al.
Am J Cardiol
. 2024 Jan;
214:94-104.
PMID: 38185438
This analysis aimed to evaluate the effect of 1- versus 3-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in older patients. Data from 3 prospective, single-arm studies (XIENCE...
6.
Zahr F, Smith R, Gillam L, Chadderdon S, Makkar R, von Bardeleben R, et al.
JACC Cardiovasc Interv
. 2023 Nov;
PMID: 37962288
Background: The CLASP IID (Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical) trial is the first randomized controlled trial comparing the PASCAL system and the MitraClip system in prohibitive risk...
7.
Smith R, Lim D, Gillam L, Zahr F, Chadderdon S, Rassi A, et al.
JACC Cardiovasc Interv
. 2023 Oct;
16(23):2820-2832.
PMID: 37905772
Background: Favorable 6-month outcomes from the CLASP IID Registry (Edwards PASCAL transcatheter valve repair system pivotal clinical trial) demonstrated that mitral valve transcatheter edge-to-edge repair with the PASCAL transcatheter valve...
8.
Valgimigli M, Spirito A, Sartori S, Angiolillo D, Vranckx P, de la Torre Hernandez J, et al.
JACC Cardiovasc Interv
. 2023 Oct;
16(20):2498-2510.
PMID: 37804290
Background: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients on long-term oral anticoagulation (OAC) therapy is still uncertain. Objectives: The aim of this...
9.
Goel K, Lindenfeld J, Makkar R, Naik H, Atmakuri S, Mahoney P, et al.
J Am Coll Cardiol
. 2023 Sep;
82(13):1281-1297.
PMID: 37730284
Background: Real-world applicability of the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) randomized controlled trial (RCT) has been debated because...
10.
Lakkireddy D, Thaler D, Ellis C, Swarup V, Gambhir A, Hermiller J, et al.
JACC Cardiovasc Interv
. 2023 Aug;
16(15):1902-1913.
PMID: 37587599
Background: The Amulet (Abbott) left atrial appendage occluder investigational device exemption trial is the largest randomized trial evaluating the safety and effectiveness of the Amulet left atrial appendage occluder compared...